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Abstract
Uterine carcinosarcomas (UCS) are rare
tumors. Consensus regarding therapeutic
management in non-metastatic disease is
lacking. This study reports on outcome and
predictive factors when using postoperative
radiotherapy. We analyzed a retrospective
analysis in 124 women treated between 1987-
2007 in the framework of the Rare-Cancer-
Network. Median follow-up was 27 months.
Postoperative pelvic EBRT was administered
in 105 women (85%) and 92 patients (74%)
received exclusive or additional vaginal
brachytherapy. Five-year overall survival (OS),
disease-free survival (DFS), cancer specific
survival (CSS) and locoregional control (LRC)
were 51.6% (95% CI 35-73%), 53.7% (39-71%),
58.6% (38-74%) and 48% (38-67%).
Multivariate analysis showed that external
beam radiation therapy (EBRT) >50Gy was an
independent prognostic factor for better OS
(P=0.03), CSS (P=0.02) and LRC (P=0.01).
Relative risks (RR) for better OS (P=0.02),
DFS (P=0.04) and LRC (P=0.01) were signifi-
cantly associated with younger age (≤60
years). Higher brachytherapy (BT)-dose
(>9Gy) improved DFS (P=0.04) and LRC
(P=0.008). We concluded that UCS has high
systemic failure rate. Local relapse was
reduced by a relative risk factor of over three in
all stages of diseases when using higher doses
for EBRT and brachytherapy. Postoperative RT
was most effective in UCS stage I/II-diseases.
Introduction
Uterine carcinosarcoma (UCS) is a rare but
aggressive tumor entity, comprising of both
malignant epithelial and mesenchymal compo-
nents, accounting for 1-2% of uterine cancers.1
According to the NCCN guidelines UCS is no
longer recognized as a sarcoma due to its prob-
able epithelial origin.2,3 Therefore it is includ-
ed in the high-risk malignant endometrial
tumors section. The disease affects primarily
postmenopausal women after sixty years of
age.4 Potential risk factors include excess
estrogen exposure in relation to obesity, dia-
betes and high-fat diet, nulliparity, prior pelvic
radiotherapy and tamoxifen use.2,5 Women
present with non-specific symptoms including
vaginal bleeding, pain and swelling of the
lower abdomen. Reported five-year survival
rates are between 30-40%.6 About 35% of carci-
nosarcomas are not confined to the uterus at
diagnosis with corresponding median survival
of 21 months.7 Diagnostic work-up includes
ultrasound, computed tomography (CT) and
magnetic resonance imaging (MRI). There are
no distinct radiological features that discrimi-
nate UCS from other uterine malignancies.
UCS generally show FDG-uptake and FDG-PET
may be used for diagnostic and staging purpos-
es.8 For patients without evidence of metastat-
ic disease, the standard treatment includes
total hysterectomy with bilateral salpingo-
oophorectomy (BSO), pelvic and para-aortic
lymphadenectomy, cytology of peritoneal wash-
ings, omentectomy and biopsies of the peri-
toneal surfaces. For women with extrauterine
disease limited to the peritoneum surgical
cytoreduction may be recommended.2
Optimal management remains unclear.6
Early stage of disease has been identified as
most relevant element for treatment outcome.9
The aim of this Rare Cancer Network (RCN)
study was to assess UCS recurrence pattern
according to stage and treatment in an effort to
evaluate the role of radiation therapy and iden-
tify predictive factors in the non-metastatic
disease.
Materials and Methods
Data from 124 patients with UCS treated
between 1987 and 2007 at eleven institutions
from Australia, France, Israel, Switzerland and
Turkey were collected. Each institution in their
respective country obtained ethics approval.
Patients who underwent hysterectomy with or
without BSO were included. Besides observa-
tion, postoperative treatment consisted of,
brachytherapy (BT), External beam radiation
therapy (EBRT), and/or adjuvant chemothera-
py (ChT). The choice of adjuvant therapy was
based on physician preferences. Patients treat-
ed with palliative intent were excluded. As rec-
ommended by the FIGO committee on gyneco-
logic oncology in 2009, UCS was staged as car-
cinoma of the endometrium.3 The medical
records of all patients with UCS were reviewed
to identify patient and tumor characteristics,
treatment details, and follow-up (FU).Statistical analysis
Data were analyzed using χ2 tests. Variables
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significant in the univariate analysis were
subsequently entered into a multivariate
analysis (MVA) using the Cox proportional
hazards ratio model. Disease-free survival
(DFS), Cancer specific survival (CSS), locore-
gional control (LRC), and overall survival (OS)
were calculated from the date of diagnosis to
the date of progression, date of death, or date
of last follow-up if the patient was alive. Time
to any event was measured from the date of
diagnosis. Kaplan-Meier curves were generat-
ed from the survival data. Statistical analysis
was performed using SPSS software for
Windows version 12.0 (SPSS, Chicago, IL,
USA). A P-value of <0.05 was considered sta-
tistically significant for all tests.
Results
Patient demographics
Data from 124 patients with UCS were ana-
lyzed and summarized in Table 1.Diagnostics, surgical treatment and pathologic findings
In 41 cases (33%), diagnosis was known due
to biopsy or curettage. For the majority of
patients (67%), UCS was diagnosed on the sur-
gical specimen. The first-line treatment for all
patients was total hysterectomy. With the
exception of two, all patients underwent BSO.
Lymph node sampling or pelvic lymph node dis-
section (PLND) was performed in 76 patients
(61.3%), and lymph node metastases were
found in 15 patients (13%). Surgical resection
margins were positive in 12 patients (9.7%), of
these five patients developed local recurrence
in the later course of disease. For 20 patients
operative margin status was unknown. Sixty-
four patients (51.6%) had FIGO 20093 stage I,
17 (13.7%) stage II, 35 (28.2%) stage III, and
four patients presented with stage IV disease
(Table 1).Postsurgical treatment
Thirteen patients (10.5%) received no post-
operative RT (Table 1). EBRT was adminis-
tered to 105 patients (84.7%). The mean total
dose was 48.4 Gy (range, 9-59 Gy, median 50.4
Gy). In 104 patients (83.9%), EBRT included
pelvic lymph node areas. In the one remaining
case EBRT was limited to the tumor bed only.
In 86 female patients (69.4%), EBRT was asso-
ciated with BT at a mean dose of 16.1 Gy
(range, 6-34 Gy, median 16.0 Gy). Six patients
(4.8%) underwent postoperative vaginal cuff
high-dose-rate (HDR) BT alone at total mean
doses of 29.4 Gy (range 21-34 Gy) Gy. Twenty-
five patients (20.2%) underwent adjuvant ChT
mainly consisting of ifosfamide-based ChT.
Outcomes
The mean follow-up (FU) time was 40
months (range, 9-164 months, median 27
months). At the end of RT, 103 patients (83%)
had no evidence of disease. Fourteen patients
(11%) presented rapid systemic progression,
and seven showed (6%) stable disease.
Seventy-six patients were alive at last FU,
and 14 of them had relapsed. Forty-eight
patients died: Seventeen due to UCS and 31
due to other reasons. Five-year OS, DFS and
CSS rates for the entire cohort were 51.6%
[95% confidence interval (CI) 35-67%], 53.7%
(95% CI 39-71%) and 58.6% (95% CI 38-74%),
respectively (Figure 1).
During FU, 20 patients (16.1%) relapsed
both locally and systemically, 10 patients
(8.1%) relapsed loco-regional, whereas 27
patients (21.7%) showed systemic relapse
only. The median time to recurrence was 25
months (range, 2-159 months). Thirty-one
patients had pelvic recurrence. The 5-year LRC
rate was 48%. Ten patients had only loco-
regional recurrence and none were retreated
with RT. Metastatic disease occurred in 45
patients (36%). The metastatic sites were as
follows: lung (31%), liver (15%), bones/ mus-
cles (17%), peritoneum (29%) and brain (8%).
On univariate analysis, PLND showed a ben-
efit for DFS, CSS and LRC (Table 2). EBRT and
BT dose resulted in improved OS, DFS, CSS ad
LRC. Early Stage I/II disease as well as younger
age (<60 years) at diagnosis had significant
beneficial effects on OS, DFS, CSS and LRC.
However, CSS did not differ when comparing
stage I/II with stage III/IV disease (Table 2).
MVA showed that EBRT>50 Gy was an inde-
pendent predictive factor for better OS
(P=0.03), CSS (P=0.02) and LRC (P=0.01),
reducing the relative risks (RR) by a factor of
3.6 for LRC. Patients with stage I/II compared
to stage III/IV disease showed improved OS
(P=0.03) and DFS (P=0.03). Early or advanced
tumor stage did not cause different CSS, how-
ever. Age <60 years was predictive for better
LRC (P=0.01), DFS (P=0.04) and OS (P=0.02).
PLND also had a favorable impact on DFS
(P=0.03). BT dose higher than 9 Gy signifi-
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Table 1. Patient, tumor and treatment characteristics.
Characteristic                                                                         N=124
Age years, median (range)                                                                        66.5 (50-88)
Postmenopausal status                                                                                 116 (94)
Symptoms at diagnosis                                                                                          
       Bleeding                                                                                                      102 (82)
       Pain                                                                                                               18 (15)
       Tamoxifen intake history                                                                         17 (14)
FIGO Stage (2009)                                                                                                 
      IA                                                                                                                   38 (30)
      IB                                                                                                                   26 (21)
      II                                                                                                                    17 (14)
      All stage I/II                                                                                                 81 (65)
      IIIA                                                                                                                17 (14)
      IIIB                                                                                                                  3 (2)
      IIIC                                                                                                                15 (12)
      IV                                                                                                                     4 (3)
      All stage III/IV                                                                                             39 (32)
      Unknown                                                                                                        4 (3)
Surgery                                                                                                                       
       Hysterectomy                                                                                                 124
       Salpingo-oophorectomy                                                                          122 (98)
       Pelvic nodal evaluation                                                                             76 (61)
       Positive margin                                                     12 (9) [20 pts without info concerning margins]
Radiation therapy                                                                                                   
      No adjuvant RT                                                                                           13 (10)
      Adjuvant RT                                                                                                111 (90)
      EBRT only                                                                                                    19 (15)
      EBRT+BT                                                                                                    86 (69)
      BT only                                                                                                           6 (3)
Interruption >5 days                                                                                       14 (11)
Mean EBRT dose (Gy)                                                        48.4 (range, 9-59 Gy, median 50.4 Gy)
Mean BT dose (Gy)                                                              16.1 (range, 6-34 Gy, median 16.0 Gy)
Adjuvant chemotherapy                                                                                  25 (20)
Hormonal treatment                                                                                        13 (10)
FIGO, International Federation of Gynecology and Obstetrics; RT, Radiation therapy; EBRT, External beam radiation therapy; BT, Brachytherapy;
pts, Patients. Values are numbers (percentage) unless otherwise noted.
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cantly ameliorated LRC (P=0.008) and DFS
(P=0.04); no difference was detected for OS
and CSS (Table 2).
None of the other analyzed variables, name-
ly hormonal therapy, tamoxifen intake history,
menopausal status, and operative margin sta-
tus, had a significant influence on DFS, LRC,
CSS or OS. It is of interest that 13.7% of
patients included had a history of prior breast
cancer and tamoxifen exposure.
Acute and late toxicity was scored according
to the CTCAE v.3.0. Grade >1 acute toxicity was
observed in 41 patients. Most of these compli-
cations were mild or moderate. Late toxicity
was poorly documented. 
Discussion
Surgery is the first treatment option for UCS
providing effective disease control.2,10 However,
local recurrence rate for early stage disease
yields between 40-60% showing the aggressive
potential of the disease. Despite the risk for
early metastases due to occult distant disease
at time of diagnosis justifying the use of adju-
vant systemic treatment,4,11 better local tumor
control is needed. The randomized trial
(EORTC 55874) and several retrospective stud-
ies, showed that postoperative RT improves
LRC (Table 3).6,10,12-19 Reed and colleagues
demonstrated in the EORTC 55874 study that
for UCS stage I/II local relapse at any time was
reduced by half using postoperative RT com-
pared to observation.12 Callister and colleagues
confirmed in their retrospective study of 300
operable patients with stage I-III disease that
pelvic RT increased the 5-year LCR from 28%
to 48% compared to surgery alone, and time to
any distant relapse was prolonged (17.3 vs. 7.0
months).6 Sampath and colleagues showed in
a retrospective analysis of 3650 patients (stage
I/II/III: 49%), that postoperative RT conferred a
53% risk reduction in local failure at five years
for all uterine sarcoma types compared to sur-
gery. Brown and colleagues showed recently
                             Article
Figure 1. Five-year overall survival rates (A) and disease-free survival rates (B) in patients presenting with uterine carcinosarcoma.
A B
Table 2. Analysis of predictive factors for overall survival, cancer-specific survival, disease-free survival and locoregional control.
5-year outcome                                         OS 51.6%                           CSS 58.6%                      DFS 53.7%                            LRC 48.0%
                                                              (95%CI 35-73%)                (95%CI 38-74%)             (95%CI 39-71%)                  (95%CI 38-67%)
Multivariate analysis, P-value (RR)                                                                                                                                                                                                           
          PLND                                                                     0.08 (1.9)                                       0.03 (2.6)                                   0.03 (2.3)                                         0.05 (2.0)
          Dose EBRT >50 Gy                                            0.03 (2.5)                                       0.02 (2.2)                                   0.06 (1.8)                                         0.01 (3.6)
          Dose BT ≤9Gy vs. ≥9Gy                                     0.1 (1.5)                                        0.08 (1.7)                                   0.04 (2.1)                                        0.008 (5.1)
          FIGO stage I-II vs. III-IV                                   0.01 (3.3)                                               -                                           0.03 (2.4)                                         0.07 (1.7)
          Age ≤60 vs. ≥ 60 years                                       0.02 (3.9)                                       0.05 (1.7)                                   0.04 (2.2)                                         0.01 (4.3)
Univariate analysis %, P value (95 CI)                                                                                                                                                                                                     
         Chemotherapy                                                  0.15 (24-79)                                   0.64 (33-81)                              0.29 (38-70)                                     0.23 (34-71)
         PLND                                                                    0.1 (36-73)                                    0.01 (31-77)                              0.02 (33-72)                                     0.01 (26-63)
         Dose Brachytherapy                                        0.01 (32-76)                                   0.04 (36-75)                            <0.001 (36-71)                                <0.001 (30-76)
         Surgical resection margin                              0.32 (27-84)                                   0.17 (30-76)                              0.39 (37-74)                                     0.28 (36-69)
         Pelvic lymph node RT                                      0.42 (37-76)                                   0.61 (30-69)                              0.56 (37-70)                                     0.12 (29-72)
         RT treatment interruption >5 days             0.45 (38-81)                                   0.72 (37-80)                              0.68 (36-71)                                     0.22 (38-81)
         EBRT                                                                   0.91 (38-74)                                   0.82 (34-76)                              0.88 (38-73)                                     0.76 (23-73)
         Premenopausal status                                    0.14 (29-74)                                   0.20 (26-77)                              0.10 (37-70)                                     0.12 (34-71)
         Dose postoperative RT                                <0.001 (30-71)                               0.009 (32-79)                           <0.001 (34-62)                                <0.001 (23-66)
         Stage I/II vs. III/IV                                            0.04 (30-76)                                   0.05 (28-75)                              0.04 (32-68)                                     0.04 (31-70)
         Age at diagnosis                                               0.02 (33-74)                                   0.04 (27-78)                              0.01 (36-63)                                     0.02 (34-67)
OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; LRC, locoregional control; RR, relative risk; PLND, pelvic lymph node dissection; CI, confidence interval; Other abbreviations as in Table 1.
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that even in UCS stage I/II relapse occurred in
33% after BT without external RT.13 Node-neg-
ative patients receiving postoperative RT had
significantly less local failures.10 Better LRC
comes at the cost of toxicity. In our study irra-
diated patients reported increased early toxici-
ty (CTCAE Grade >1: 33%), but no severe late
side effects were reported. However, late toxic-
ity was only poorly documented in our trial.
The EORTC 55874 study observed as well pri-
marily increased early toxicity with low rate of
late toxicity.12 Sorbe and colleagues demon-
strated increased early and 5-10% late side
effects (bladder and intestine) when applying
pelvic RT as reported in the PORTEC-1 trial.20,21
The role of dose escalation in UCS to ame-
liorate disease control is unclear. We showed
that EBRT dose ≥50 Gy and BT dose ≥9 Gy
improved LRC, CSS and OS in UCS (Table 2).
In the EORTC 55874 randomized study, EBRT
dose of 50.4 Gy improved local control. Some
patients with stage I/II disease were escalated
up to 65 Gy. It remains unanswered if local con-
trol improved.12 A retrospective study by Livi
and colleagues indicated that a dose ≥50 Gy
reduced local recurrence. Yoney and col-
leagues observed in their retrospective study
including 105 patients with uterine sarcoma
(27.6% UCS) that postoperative RT >54 Gy
improved OS.22 Other groups observed similar
correlations suggesting that UCS is a
radiosensitive tumor and tumor response is
dose dependent.17,23 Importantly, local recur-
rence at three years was lowest for patients
receiving EBRT and BT highlighting the
importance of BT as a boost technique to esca-
late the dose without increasing toxicity
rates.17 If BT as a single postoperative treat-
ment could compensate for the omission of
EBRT remains to be tested.20 Our data indicate
that BT dose ≥9 Gy improves local control and
DFS irrespective of EBRT (Table 2). However,
there might be a bias that patients included
with residual postoperative tumor or surgical
resection margin positive disease, were treat-
ed with a higher BT dose. As UCS is staged as
high-risk endometrial carcinoma and depend-
ing on risk factors combination of EBRT and
BT remains standard to date.2,3,17 However,
postoperative BT correlates with increased
toxicity in high-risk endometrial cancer.24
Prospective studies evaluating dose escalation
using modern RT techniques do not exist to
date and the impact of higher dose on disease
outcome is awaited. Combination of modern
image-guided radiation techniques and CT or
MR-guided brachytherapy should allow for safe
dose escalation for better local control without
increasing toxicity.25
The effect of postoperative RT on OS or CSS
in UCS remains controversial. Neither the
GOG 150 nor the EORTC 55874 randomized
trial demonstrated improved OS or CSS using
postoperative RT compared to adjuvant ChT or
observation.11,12 Sampath and colleagues
reported a 5-year OS of 37% irrespective of
using postoperative RT.10 Callister and col-
leagues demonstrated that neither postopera-
tive EBRT or BT nor adjuvant ChT significantly
ameliorated 5-year OS of only 31%, similar
CSS was 33% (Table 3). In contrast, our data
showed that postoperative RT resulted in a five
year OS of 51.6% (95% CI 35-73%) and CSS of
58.6% (95% CI 38-74%) offering one of the
highest OS and CSS in literature to date.
However, these findings should be read with
caution due to small cohort size and potential
selection bias for medically fitter patients
undergoing RT.26 A recently published large
population-based database by Patel and col-
leagues showed that the type of radiotherapy
was not associated with OS or CSS.14
The role of RT in the context of pelvic or
para-aortic lymph node dissection with respect
to OS is poorly studied. Using the Survey,
Epidemiology and End Results data base,
Nemani and colleagues demonstrated that
lymph node dissection improved five year OS
from 34% to 49% irrespective of RT.27 Our data
could not demonstrate better OS with PLND in
combination with postoperative RT, however
PLND predicted improved DFS and CSS (Table
2). This has been shown as well in the work
from Harano and colleagues that PLND was
associated with improved survival.15 An impor-
tant difference was that 61% of our patients
underwent lymph node staging or lym-
phadenectomy reducing risk of occult lymph
node disease. In the EORTC 55874 study only
25% of irradiated patients underwent node
sampling, leaving a higher risk for residual
disease in place.12 Therefore selection bias
operating and removing positive lymph nodes
on more robust patients had to be considered
that could explain our findings rather than a
beneficial effect of pelvic RT.28 Unfortunately,
we were not able to differentiate locations of
failure rate within the pelvis (tumor bed or
lymph nodes). The role of routine lym-
phadenectomy is an ongoing debate for UCS
and could not be answered in this study.27,28
Another focus of this work was to define pre-
dictive factors to determine effectiveness of
postoperative RT in UCS. In our study stage I/II
disease was predictive for improved DFS and
OS indicating that early diagnosis and multi-
modality treatment improves outcome (Table
2). In contrast to the more favorable outcome
of early stage disease, UCS stages III and IV
diseases have a high potential of haematoge-
nous spread most likely limiting the potential
of postoperative RT to improve outcome. More
effective systemic treatment regimens are
needed to compensate for early metastases.28
Other predictive factors identified that corre-
lated with ameliorated OS or CSS were patient
age <60 years, PLND and EBRT ≥50 Gy. BT
dose was highly predictive for better local con-
trol, indicating the importance of a high dose
to the vaginal vault to help to sterilize the
tumor bed area.21 Several retrospective studies
confirmed that postoperative RT, higher dose,
lymph node assessment, adnexal involvement,
histologic grade, surgery and disease stage
were relevant factors evaluating disease out-
come and treatment response for either LRC or
survival as summarized in Table 3.6,10-20,27,29,30
Future trial design using RT for UCS should be
guided by these findings to find the patient
group that benefit most from intensified adju-
vant treatment modalities.
This study has several limitations. This was
a retrospective analysis with a pool of patients
from different countries and treatment regi-
mens with varied inherent selection bias
toward treatment. The impact of adjuvant ChT
on outcome in this disease could not be
addressed in its full extent as treatment regi-
mens were only partially reported. Similar
long-term toxicities were not fully available.
Despite these limitations we believe our study
contributes to a better understanding of the
role of postoperative RT in UCS.
Conclusions
Postoperative RT in our work had an impact
on disease outcome. Despite the unfavorable
prognosis of UCS, local relapse could be pre-
vented by a relative risk factor of over three
when using higher doses for EBRT as well as
BT. Therefore use of postoperative RT should
be considered as part of a multidisciplinary
approach to therapy for early stage UCS.
Image-guided radiation techniques for dose
escalation without increasing toxicity should
be used in future trials.
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